161 related articles for article (PubMed ID: 23071531)
1. SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas.
Idbaih A; Ducray F; Dehais C; Courdy C; Carpentier C; de Bernard S; Uro-Coste E; Mokhtari K; Jouvet A; Honnorat J; Chinot O; Ramirez C; Beauchesne P; Benouaich-Amiel A; Godard J; Eimer S; Parker F; Lechapt-Zalcman E; Colin P; Loussouarn D; Faillot T; Dam-Hieu P; Elouadhani-Hamdi S; Bauchet L; Langlois O; Le Guerinel C; Fontaine D; Vauleon E; Menei P; Fotso MJ; Desenclos C; Verrelle P; Ghiringhelli F; Noel G; Labrousse F; Carpentier A; Dhermain F; Delattre JY; Figarella-Branger D;
PLoS One; 2012; 7(10):e45950. PubMed ID: 23071531
[TBL] [Abstract][Full Text] [Related]
2. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas.
Sahm F; Koelsche C; Meyer J; Pusch S; Lindenberg K; Mueller W; Herold-Mende C; von Deimling A; Hartmann C
Acta Neuropathol; 2012 Jun; 123(6):853-60. PubMed ID: 22588899
[TBL] [Abstract][Full Text] [Related]
3. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
4. Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization.
Jeon YK; Park K; Park CK; Paek SH; Jung HW; Park SH
Neuropathology; 2007 Feb; 27(1):10-20. PubMed ID: 17319279
[TBL] [Abstract][Full Text] [Related]
5. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization.
Bigner SH; Matthews MR; Rasheed BK; Wiltshire RN; Friedman HS; Friedman AH; Stenzel TT; Dawes DM; McLendon RE; Bigner DD
Am J Pathol; 1999 Aug; 155(2):375-86. PubMed ID: 10433931
[TBL] [Abstract][Full Text] [Related]
6. Molecular Analysis of Pediatric Oligodendrogliomas Highlights Genetic Differences with Adult Counterparts and Other Pediatric Gliomas.
Nauen D; Haley L; Lin MT; Perry A; Giannini C; Burger PC; Rodriguez FJ
Brain Pathol; 2016 Mar; 26(2):206-14. PubMed ID: 26206478
[TBL] [Abstract][Full Text] [Related]
7. Ki-67 and MCM6 labeling indices are correlated with overall survival in anaplastic oligodendroglioma, IDH1-mutant and 1p/19q-codeleted: a multicenter study from the French POLA network.
Pouget C; Hergalant S; Lardenois E; Lacomme S; Houlgatte R; Carpentier C; Dehais C; Rech F; Taillandier L; Sanson M; Appay R; Colin C; Figarella-Branger D; Battaglia-Hsu SF; Gauchotte G
Brain Pathol; 2020 May; 30(3):465-478. PubMed ID: 31561286
[TBL] [Abstract][Full Text] [Related]
8. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
Cairncross JG; Ueki K; Zlatescu MC; Lisle DK; Finkelstein DM; Hammond RR; Silver JS; Stark PC; Macdonald DR; Ino Y; Ramsay DA; Louis DN
J Natl Cancer Inst; 1998 Oct; 90(19):1473-9. PubMed ID: 9776413
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel population in high-grade oligodendroglial tumors not deleted on 1p/19q using array CGH.
Talagas M; Marcorelles P; Uguen A; Redon S; Quintin-Roué I; Costa S; Férec C; Morel F; Hieu PD; De Braekeleer M
J Neurooncol; 2012 Sep; 109(2):405-13. PubMed ID: 22825724
[TBL] [Abstract][Full Text] [Related]
10. Loss of heterozygosity at 1p-19q induces a global change in oligodendroglial tumor gene expression.
Ferrer-Luna R; Mata M; Núñez L; Calvar J; Dasí F; Arias E; Piquer J; Cerdá-Nicolás M; Taratuto AL; Sevlever G; Celda B; Martinetto H
J Neurooncol; 2009 Dec; 95(3):343-354. PubMed ID: 19597701
[TBL] [Abstract][Full Text] [Related]
11. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression.
Hoang-Xuan K; He J; Huguet S; Mokhtari K; Marie Y; Kujas M; Leuraud P; Capelle L; Delattre JY; Poirier J; Broët P; Sanson M
Neurology; 2001 Oct; 57(7):1278-81. PubMed ID: 11591848
[TBL] [Abstract][Full Text] [Related]
12. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
[TBL] [Abstract][Full Text] [Related]
13. P18 tumor suppressor gene and progression of oligodendrogliomas to anaplasia.
He J; Hoang-Xuan K; Marie Y; Leuraud P; Mokhtari K; Kujas M; Delattre JY; Sanson M
Neurology; 2000 Sep; 55(6):867-9. PubMed ID: 10994011
[TBL] [Abstract][Full Text] [Related]
14. Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas.
Godfraind C; Rousseau E; Ruchoux MM; Scaravilli F; Vikkula M
Neuropathol Appl Neurobiol; 2003 Oct; 29(5):462-71. PubMed ID: 14507338
[TBL] [Abstract][Full Text] [Related]
15. Identification of oligodendroglioma specific chromosomal copy number changes in the glioblastoma MI-4 cell line by array-CGH and FISH analyses.
Magnani I; Moroni RF; Roversi G; Beghini A; Pfundt R; Schoenmakers EF; Larizza L
Cancer Genet Cytogenet; 2005 Sep; 161(2):140-5. PubMed ID: 16102584
[TBL] [Abstract][Full Text] [Related]
16. Network-based analysis of oligodendrogliomas predicts novel cancer gene candidates within the region of the 1p/19q co-deletion.
Gladitz J; Klink B; Seifert M
Acta Neuropathol Commun; 2018 Jun; 6(1):49. PubMed ID: 29890994
[TBL] [Abstract][Full Text] [Related]
17. Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity.
Baumgarten P; Harter PN; Tönjes M; Capper D; Blank AE; Sahm F; von Deimling A; Kolluru V; Schwamb B; Rabenhorst U; Starzetz T; Kögel D; Rieker RJ; Plate KH; Ohgaki H; Radlwimmer B; Zörnig M; Mittelbronn M
Neuropathol Appl Neurobiol; 2014 Feb; 40(2):205-16. PubMed ID: 24117486
[TBL] [Abstract][Full Text] [Related]
18. Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome.
Kros JM; Gorlia T; Kouwenhoven MC; Zheng PP; Collins VP; Figarella-Branger D; Giangaspero F; Giannini C; Mokhtari K; Mørk SJ; Paetau A; Reifenberger G; van den Bent MJ
J Neuropathol Exp Neurol; 2007 Jun; 66(6):545-51. PubMed ID: 17549014
[TBL] [Abstract][Full Text] [Related]
19. Oligodendrogliomas: new insights from the genetics and perspectives.
Alentorn A; Sanson M; Idbaih A
Curr Opin Oncol; 2012 Nov; 24(6):687-93. PubMed ID: 22913971
[TBL] [Abstract][Full Text] [Related]
20. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
